Evaluating New Immunotherapy Combinations for Advanced Liver Cancer Treatment
NCT04524871 · RecruitingThis study looks at the effectiveness and safety of different combinations of immunotherapy for patients with advanced liver cancers. It includes participants with a type of liver cancer called hepatocellular carcinoma, who have not had previous systemic treatment. The study is flexible, meaning it can add or change treatments based on how well they work or if new options become available.
Locations and contact
This trial is running at 33 locations in 7 countries. 24 of them are currently recruiting.
United States16 locations · 14 recruiting
- Cherry Creek Medical CenterAurora, ColoradoRecruiting
- City of HopeDuarte, CaliforniaRecruiting
- Georgetown University Medical CenterWashington D.C., District of ColumbiaRecruiting
- Oregon Health & Science UniversityPortland, OregonRecruiting
- Parkland Health & Hospital SystemDallas, TexasRecruiting
- Smilow Cancer Hospital at Yale New HavenNew Haven, ConnecticutRecruiting
- The University of Texas Southwestern Medical Center at DallasDallas, TexasRecruiting
- UC Irvine Medical CenterCosta Mesa, CaliforniaRecruiting
- UCHealth Cancer Center Pharmacy - Highlands Ranch HospitalHighlands Ranch, ColoradoRecruiting
- UCLA Center for EastSanta Monica, CaliforniaRecruiting
- University of California San Diego Medical CenterSan Diego, CaliforniaRecruiting
- University of California San Francisco Cancer CenterSan Francisco, CaliforniaRecruiting
- University of Colorado Hospital - Anschutz Cancer PavilionAurora, ColoradoRecruiting
- University of Kentucky - Markey Cancer CenterLexington, KentuckyRecruiting
- Sarah Cannon Research Institute / Tennessee OncologyNashville, TennesseeCompleted
- UC Irvine Medical CenterOrange, CaliforniaCompleted
Israel4 locations · 4 recruiting
- Davidof Center - Rabin Medical CenterPetah TikvaRecruiting
- Hadassah University Medical CenterJerusalemRecruiting
- Rambam Medical CenterHaifaRecruiting
- Sourasky Medical CentreTel AvivRecruiting
South Korea4 locations · 2 recruiting
- Asan Medical CenterSeoulRecruiting
- Samsung Medical CenterSeoulRecruiting
- CHA Bundang Medical CenterGyeonggi-doActive Not Recruiting
- Seoul National University HospitalSeoulWithdrawn
Taiwan2 locations · 2 recruiting
- National Cheng Kung University HospitalTainanRecruiting
- National Taiwan University HospitalTaipeiRecruiting
France4 locations · 1 recruiting
- CHU Hôpitaux de MarseilleMarseilleRecruiting
- Centre Eugène MarquisRennesActive Not Recruiting
- Centre Georges Francois LeclercDijonActive Not Recruiting
- Gustave RoussyVillejuifActive Not Recruiting
New Zealand1 location · 1 recruiting
- Auckland City HospitalAucklandRecruiting
China2 locations
- Beijing Cancer HospitalBeijingActive Not Recruiting
- Zhongshan Hospital Fudan UniversityShanghaiCompleted
Who can join
Adults aged 18 and older, both men and women, can join if they have advanced liver cancer and meet certain health criteria. They should not have received prior systemic treatments for their cancer. The trial team will confirm eligibility for each participant.
What happens during the trial
Participants will be randomly placed into several groups to receive different treatment combinations. These include combinations of drugs like atezolizumab and bevacizumab, and others. Everyone will receive one of the treatment combinations until they experience unacceptable side effects or their cancer shows no improvement.
The trial team
The trial is sponsored by Hoffmann-La Roche, with support from several organizations including Adagene Inc and Tempest Therapeutics. The study director is from Hoffmann-La Roche.
Important dates
The trial started on November 1, 2020. It is expected to be completed by September 30, 2027, and is currently enrolling new participants.
Additional information
The trial ID is NCT04524871. It is a Phase 1/2 study, meaning it is looking at how well the treatments work and their safety. This is an FDA-regulated study, and it aims to include about 518 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →